porfimer (Rx)

  • Print
Brand and Other Names:Photofrin

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

powder for injection

  • 75mg/vial
more...

Esophageal Cancer, Endobronchial NSCLC

2 mg/kg IV over 3-5 minutes 

Follow by corresponding spectrum of laser light 40-50 hours after injection, then again 96-120 hours after injection

Ablation of High-grade Dysplasia in Barrett's Esophagus

2 mg/kg IV over 3-5 minutes 

Follow by corresponding spectrum of laser light 40-50 hours after injection, then again 96-120 hours after injection Barrett's esophagus patients who do not undergo esophagectomy

Bladder Carcinoma (Orphan)

Photodynamic therapy of transitional cell carcinoma in situ of the urinary bladder

Orphan sponsor

  • QLT Phototherapeutics, Inc, Lederle Laboratories; 401 North Middletown Road; Pearl River, NY 10965

Cholangiocarcinoma (Orphan)

Orphan sponsor

  • Pinnacle Biologics, Inc; 2801 lakeside Drive, Suite 209; Bannockburn, IL 60015

Mesothelioma (Orphan)

Orphan designation for malignant pleural mesothelioma

Orphan sponsor

  • Pinnacle Biologics, Inc; 2801 lakeside Drive, Suite 209; Bannockburn, IL 60015

Other Indications & Uses

Ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and porfimer

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Anemia (32%)

            Fever (31%)

            Pleural effusion (28%)

            Constipation (24%)

            Chest pain (22%)

            Abd pain (20%)

            Dyspnea (18%)

            Pneumonia (16%)

            Insomnia (14%)

            Back pain (11%)

            1-10%

            Atrial-fib (10%)

            Dysphagia (10%)

            Pharyngitis (10%)

            Resp distress (9%)

            Decr wt (9%)

            Hematemesis (8%)

            Dehydration (7%)

            Hypotension (7%)

            Peripheral edema (7%)

            Cardiac failure (7%)

            Tachycardia (6%)

            Asthenia (6%)

            Hypertension (6%)

            Cough (6%)

            Diarrhea (5%)

            Generalized edema (5%)

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity to porphyrins

            Tracheoesophageal or bronchoesophageal fistula; tumor erosion into major blood vessel

            Cautions

            Separate from radiotherapy by 2-4 wk

            Avoid sunlight following injection

            Thromboembolism reported, particularly in patients with other risk factors (eg, advanced cancer, postsurgery, prolonged immobilization, CV disease)

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: not known if excreted in breast milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Activated by laser light to produce oxygen free radicals and vascular necrosis via thromboxane A2 release

            Pharmacokinetics

            Half-Life: 250 hr (retained longest in tumors, skin, and reticuloendothelial organs)

            Peak Plasma Concentration: 15 mcg/mL

            Protein Bound: 90%

            Vd: 0.49 L/kg

            Clearance: 0.051 mL/min/kg

            Metabolism: N/A

            Excretion: N/A

            Dialyzable: No

            Previous
            Next:

            Administration

            IV Incompatibilities

            Do not mix with other drugs in the same solution

            IV Preparation

            Reconstitute with 31.8 mL of either D5W or NS resulting in a final concentration of 2.5 mcg/mL & pH of 7-8

            Shake well until dissolved

            Protect the reconstituted product from bright light & use immediately

            Reconstituted porfimer is an opaque solution in which detection of particulate matter by visual inspection is extremely difficult

            IV Administration

            Administer slow IVP over 3-5 min

            Use of gloves & eye protection is recommended

            Storage

            Store intact vials at controlled room temp 20-25°C (68-77°F)

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous